Mylan's Levothyroxine Sodium Tablets Approved as a Generic Equivalent to Levoxyl(R)PITTSBURGH, July 14 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced that the U.S. Food and Drug Administration has granted approval for the company to market its currently approved Levothyroxine Sodium Tablets as a bioequivalent and therapeutically equivalent (i.e., AB-rated) product to Jones Pharma Inc.'s Levoxyl^® Tablets.

The Mylan product is currently available to the trade in 0.025 mg, 0.050 mg, 0.075 mg, 0.088 mg, 0.1 mg, 0.112 mg, 0.125 mg, 0.150 mg, 0.175 mg, 0.2 mg and 0.3 mg strengths.

Mylan is the first company to offer Levothyroxine Sodium Tablets as AB-rated to Levoxyl^®, Unithroid^® and Synthroid^®.

Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories Inc. and Mylan Bertek Pharmaceuticals Inc., that develop, manufacture and market an extensive line of generic and proprietary products.

For more information about Mylan, visit www.mylan.com.

SOURCE Mylan Laboratories Inc.
CONTACT: Heather Bresch (Media), +1-724-514-1800,
or Kris King (Investor), +1-724-514-1800, both of Mylan Laboratories Inc.

Web site: http://www.mylan.com